COVID-19大流行期间补充剂相关草酸盐肾病发生率增加
该研究回顾性分析了单中心35例经肾活检证实的继发性草酸盐肾病,比较2018-2019年与2020年至2022年初两个时间段。COVID-19大流行期间补充剂相关草酸盐肾病占比显著高于前2年(44% vs. 0%,P=0.002),与维生素C使用、饮食改变和补充剂相关。在9例明确并移除潜在致病摄入物的患者中,8例肾功能改善。
要点
- COVID-19大流行期间补充剂相关草酸盐肾病占比显著高于大流行前2年(44% vs. 0%,P=0.002)。
- 补充剂相关草酸盐肾病与维生素C使用、饮食改变和补充剂相关。
- 9例明确并移除潜在致病摄入物的患者中,8例肾功能改善。
核心结论
- COVID-19大流行期间,继发性草酸盐肾病的首要病因从肠源性高草酸尿症转向补充剂。
- 若明确并移除致病摄入物,肾脏结局优于肠源性高草酸尿症。
研究设计与样本
- 回顾性综述,比较2018-2019年(大流行前)与2020年至2022年初(大流行期间)两个时间段。
- 在单一学术机构识别35例经肾活检证实的草酸盐肾病患者(30例自体肾,5例移植肾)。
主要发现
- 补充剂相关草酸盐肾病在大流行期间占病例比例显著高于前2年(44% vs. 0%,P=0.002)。
- 补充剂相关草酸盐肾病与维生素C使用、饮食改变和补充剂相关。
- 移植肾草酸盐肾病仍与肠源性高草酸尿症、抗生素使用和脱水相关。
- 许多患者合并糖尿病(57%)、高血压(40%)和/或既存慢性肾脏病(CKD,49%)。
- 9例明确并移除潜在致病摄入物的患者中,8例肾功能改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Causes of secondary oxalate nephropathy include enteric dysfunction and excessive intake of oxalate or oxalate precursors. During the COVID-19 pandemic, there has been a dramatic rise in sales of supplements and vitamin C, during which time we observed an apparent increase in the proportion of ingestion-associated oxalate nephropathy. METHODS: We retrospectively reviewed secondary oxalate nephropathy and compared pre-pandemic (2018-2019) and pandemic (2020-early 2022) time periods. RESULTS: We identified 35 patients with kidney biopsy proven (30 native, 5 allograft) oxalate nephropathy at a single academic institution. Supplement-associated oxalate nephropathy comprised a significantly higher proportion of cases during COVID-19 pandemic compared with the preceding 2 years (44% vs. 0%, P = 0.002), and was associated with use of vitamin C, dietary changes, and supplements. Oxalate nephropathy in the kidney allograft, in contrast, remained associated with enteric hyperoxaluria, antibiotic use, and dehydration. Many patients had diabetes mellitus (57%), hypertension (40%) and/or pre-existing chronic kidney disease (CKD, 49%). Of 9 patients in which the potentially causative ingestion was identified and removed, 8 experienced improvement in kidney function. CONCLUSION: There was a shift toward supplements rather than enteric hyperoxaluria as a leading cause of secondary oxalate nephropathy during the COVID-19 pandemic. Kidney outcomes are better than those observed for enteric hyperoxaluria, if the offending agent is identified and removed.
引用
- Fong P, Wusirika R, Rueda J, et al. Increased Rates of Supplement-Associated Oxalate Nephropathy During COVID-19 Pandemic. Kidney Int Rep. 2022. PMID: 36120391. doi:10.1016/j.ekir.2022.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。